---
title: Amivantamab Compared with Real-World Physician's Choice after Platinum-Based
  Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating
  <em>EGFR</em> Exon 20 Insertion Mutations
date: '2023-11-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38001589/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231126170717&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Patients with advanced non-small cell lung cancer (NSCLC) with epidermal
  growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second
  line and beyond (2L+) have an unmet need for new treatment. Amivantamab, a bispecific
  EGFR- and MET-targeted antibody, demonstrated efficacy in this setting in the phase
  1b, open-label CHRYSALIS trial (NCT02609776). The primary objective was to compare
  the efficacy of amivantamab to the choices made by real-world physicians (RWPC)
  using ...
disable_comments: true
---
Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need for new treatment. Amivantamab, a bispecific EGFR- and MET-targeted antibody, demonstrated efficacy in this setting in the phase 1b, open-label CHRYSALIS trial (NCT02609776). The primary objective was to compare the efficacy of amivantamab to the choices made by real-world physicians (RWPC) using ...